Allist(SH:688578) Xin Lang Cai Jing·2025-09-17 02:23Core Viewpoint - The stock of Ailis has experienced fluctuations, with a year-to-date increase of 82.99% but a recent decline of 4.85% over the last five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Ailis Pharmaceutical Technology Co., Ltd. was established on March 22, 2004, and went public on December 2, 2020. The company is primarily engaged in the research, production, and sales of innovative drugs, with 99.93% of its revenue coming from drug sales [1]. - As of June 30, 2025, Ailis reported a total revenue of 2.374 billion yuan, reflecting a year-on-year growth of 50.57%, and a net profit attributable to shareholders of 1.051 billion yuan, marking a 60.22% increase [2]. Shareholder and Market Activity - As of June 30, 2025, the number of Ailis shareholders increased by 3.61% to 13,000, while the average number of circulating shares per person decreased by 3.48% to 34,578 shares [2]. - The company has distributed a total of 653 million yuan in dividends since its A-share listing [3]. - Major shareholders include various ETFs and investment funds, with notable changes in holdings among the top ten shareholders, indicating active institutional interest [3].